Document 0807
 DOCN  M9620807
 TI    Anti-CD4 activity of normal human immunoglobulin G for therapeutic use.
       (Intravenous immunoglobulin, IVIg).
 DT    9602
 AU    Hurez V; Kaveri SV; Mouhoub A; Dietrich G; Mani JC; Klatzmann D;
       Kazatchkine MD; INSERM U 28, Hopital Broussais, Paris, France.
 SO    Ther Immunol. 1994 Oct;1(5):269-77. Unique Identifier : AIDSLINE
       MED/96053309
 AB    The effects of intravenously administered normal immunoglobulin G (IVIg)
       in autoimmune diseases are dependent on the ability of IVIg to interact
       with surface molecules of lymphocytes. In the present study, we
       demonstrate the presence of anti-CD4 activity in IVIg by showing the
       ability of IVIg to bind to CD4 and to inhibit CD4-dependent cellular
       functions. Binding of IVIg to recombinant soluble human CD4 was assessed
       by ELISA, immunoblotting and real time analysis of complex formation.
       Anti-CD4 antibodies isolated from IVIg by affinity-chromatography bound
       to human CD4+ T cells. These anti-CD4 antibodies inhibited proliferative
       responses in MLR and infection of CD4+ human T cells with HIV. These
       results indicate that IVIg contains antibodies reactive with human CD4
       and that these anti-CD4 antibodies exhibit biological functions. The
       presence of anti-CD4 antibodies in IVIg may be relevant to the
       immunoregulatory effects of normal polyspecific immunoglobulin G.
 DE    Adjuvants, Immunologic  Antigens, CD4/*IMMUNOLOGY  Blotting, Western
       Fluorescent Antibody Technique, Direct  Human  HIV Infections/IMMUNOLOGY
       HIV-1/GROWTH & DEVELOPMENT  Immunoassay  Immunoglobulins,
       Intravenous/*IMMUNOLOGY  Lymphocyte Culture Test, Mixed  Protein Binding
       Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).